secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2024-07-10T23:59:59+00:00
Accession:  0001493152-24-026723
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq panel grants Vivos continued listing subject to filing Q2 Form 10-Q by Aug 15, 2024
--------------------------------------------------------------------------------

- Panel granted continued listing on Nasdaq conditional on filing Form 10-Q for quarter ended June 30, 2024 by August 15, 2024.
- Company must evidence stockholders' equity of at least $2.5 million in the Form 10-Q.
- Exploring additional equity financing to maintain compliance with Nasdaq equity requirement.
- Risk of delisting if compliance not achieved; delisting would materially harm stock price and capital access.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224026723/0001493152-24-026723-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224026723/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-026723

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer